Assessment of dabigatran plasma concentration may improve the safety of anticoagulation in patients treated with ibrutinib with concomitant atrial fibrillation

Kardiol Pol. 2020 May 25;78(5):454-457. doi: 10.33963/KP.15255. Epub 2020 Mar 24.

Authors

Ewa Lewicka¹, Paulina Daniluk², Zofia Lasocka², Ewa Zarzycka³, Alicja Dąbrowska-Kugacka², Izabela Nabiałek-Trojanowska², Jan M Zaucha³

Affiliations

¹ Department of Cardiology and Electrotherapy, Medical University of Gdańsk, Gdańsk, Poland. ewa.lewicka@gumed.edu.pl
² Department of Cardiology and Electrotherapy, Medical University of Gdańsk, Gdańsk, Poland
³ Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk, Poland

PMID: 32210217
DOI: 10.33963/KP.15255

No abstract available

MeSH terms

Adenine / analogs & derivatives
Anticoagulants / adverse effects
Atrial Fibrillation* / complications
Atrial Fibrillation* / drug therapy
Dabigatran / adverse effects
Humans
Piperidines
Plasma
Stroke
Treatment Outcome

Substances

Anticoagulants
Piperidines
ibrutinib
Dabigatran
Adenine